Salix Pharmaceuticals Reports 4Q2012 And FY2012 Results

[at noodls] – 36% Increase in Full Year Product Revenue 24% Increase in Full Year XIFAXAN® Prescriptions on a Milligram Basis 29% Increase in Full Year APRISO® Prescriptions 137% Increase in Full Year RELISTOR® Prescriptions … more

View todays social media effects on SLXP

View the latest stocks trending across Twitter. Click to view dashboard

See who Salix is hiring next, click here to view